Close Menu

National Medical Products Administration

Gilteritinib (Astellas Pharma's Xospata) is intended to treat relapsed or refractory acute myeloid leukemia patients with a FLT3 mutation.

A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.

The drug, Amelie, will be for the second-line treatment of EGFR T790-mutated non-small cell lung cancer. 

Olaparib is the first PARP inhibitor approved in China for first-line maintenance treatment of germline and somatic BRCA mutated gynecological cancers.